ADC Therapeutics SA (ADCT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, ADC Therapeutics reported revenue of $81.4M, up 14.9% from $70.8M the year before. Net income was -$142.6M (a -175.3% net margin), or -$1.12 per diluted share. Gross margin was 92.9% and operating margin was -149.3%. Operating activities generated -$141.2M of cash, leaving -$141.4M of free cash flow. At fiscal year end, ADC Therapeutics held $323.1M in total assets against $509.0M in total liabilities, including $261.3M of cash and equivalents.
Open the full interactive ADC Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
ADC Therapeutics Key Stats
| Share Price | $1.70 |
|---|---|
| Market Cap | $263.5M |
| Revenue YoY Growth | +14.8% |
| 52-Week Range | $0.96 – $4.88 |
| Shares Outstanding | 155.0 million (basic, 2026 Q2) |
ADC Therapeutics Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $69.6M | $70.8M | $81.4M |
| Cost of Goods Sold | $235.5M | $201.5M | $202.9M |
| Gross Profit | $67.0M | $64.9M | $75.6M |
| Operating Income | -$166.0M | -$130.7M | -$121.5M |
| Pre-Tax Income | -$195.4M | -$156.1M | -$141.6M |
| Income Tax | $39.1M | $166,000 | $1.0M |
| Net Income | -$240.1M | -$157.8M | -$142.6M |
| Diluted EPS | -$2.94 | -$1.62 | -$1.12 |
ADC Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $16.4M | $23.1M | $20.9M | $19.2M |
| Net Income | -$41.0M | -$6.4M | -$33.0M | -$16.6M |
| Diluted EPS | -$0.30 | -$0.05 | -$0.21 | -$0.11 |
ADC Therapeutics Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $278.6M | $250.9M | $261.3M |
| Current Assets | $336.3M | $307.4M | $306.3M |
| Total Assets | $354.8M | $322.0M | $323.1M |
| Current Liabilities | $67.7M | $80.5M | $70.2M |
| Total Long-Term Debt | $112.7M | $113.6M | $118.5M |
| Total Liabilities | $503.0M | $524.6M | $509.0M |
| Shareholders' Equity | -$148.2M | -$202.6M | -$185.8M |
ADC Therapeutics Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$118.7M | -$123.8M | -$141.2M |
| Cash From Investing | -$3.2M | -$867,000 | $395,000 |
| Cash From Financing | $73.9M | $97.1M | $150.9M |
| Free Cash Flow | -$121.9M | -$124.7M | -$141.4M |
Figures from ADC Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full ADC Therapeutics financials page for every line item.
ADC Therapeutics Company Profile
| Ticker | ADCT |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Epalinges, Switzerland |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001771910 |
Frequently Asked Questions
What was ADC Therapeutics' revenue in fiscal 2025?
ADC Therapeutics (ADCT) reported revenue of $81.4M for fiscal 2025.
What is ADC Therapeutics' annual revenue history?
ADC Therapeutics' annual revenue by fiscal year: 2023: $69.6M; 2024: $70.8M; 2025: $81.4M.
What was ADC Therapeutics' net income in fiscal 2025?
ADC Therapeutics reported net income of -$142.6M for fiscal 2025.
What was ADC Therapeutics' earnings per share (EPS) in fiscal 2025?
ADC Therapeutics' diluted EPS was -$1.12 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did ADC Therapeutics generate in fiscal 2025?
ADC Therapeutics generated -$141.4M of free cash flow in fiscal 2025.
What was ADC Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), ADC Therapeutics reported revenue of $19.2M.
How much debt does ADC Therapeutics have?
ADC Therapeutics reported $118.5M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of ADC Therapeutics are outstanding?
ADC Therapeutics reported a weighted average of 155.0 million basic shares outstanding in 2026 Q2.
What is ADC Therapeutics' market cap?
Based on its latest closing price, ADC Therapeutics (ADCT) has a market capitalization of about $263.5M.
When does ADC Therapeutics' fiscal year end?
ADC Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is ADC Therapeutics headquartered?
ADC Therapeutics lists its business address in Epalinges, Switzerland in its SEC filings.